Keiretsu Capital — 2020 Investments
3 investments dated 2020 · listed companies and verified rows first · show all
Eternatear develops diagnostic and therapeutic products for dry eye disease, particularly targeting Meibomian Gland Dysfunction.
BiotechHealthtechMedical DevicesRaleigh, US
Timothy Willis(Chief Executive Officer & Chairman of the Board)Kent Geer(Chief Financial Officer & Secretary)Tim Willis(CEO, Chairman of the Board)Ralph Stone(Chief Technology Officer)Joe Huber(Chief Operating Officer)Diethart Reichardt(Chief Marketing Officer & Board Director)
Co-investorsArieal Southeast Angel PartnersCharlotte Angel FundDuke Capital PartnersKleinmuntz AssociatesBand of AngelsCarolina Angel Network+2 more
OtoNexus Medical Technologies is developing an ultrasound-based otoscope (Novoscope) that uses a miniaturized sensor in a single-use ear speculum tip to give clinicians objective, point-of-care data on middle-ear fluid and infection type.
AI & Machine LearningDigital HealthHardwareHealthtechMedical DevicesSeattle, US
Caitlin Cameron(Chair & CEO)in
Co-investorsGolden SeedsCatalytic Impact FoundationDellin InvestmentsFarvatn VentureKeiretsu ForumMindshift Capital+5 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.









